Close Menu

helicase-dependent amplification

Great Basin this week announced the opening of a new manufacturing facility for its recently launched molecular diagnostics system and first test.

BioHelix is developing a low-cost, handheld, real-time fluorescence detection system capable of running assays based on the company's isothermal helicase-dependent amplification technology, the company disclosed this week.

Scientists from Great Basin Scientific and three university medical schools and hospitals have published research demonstrating that Great Basin's molecular diagnostic test for Clostridium difficile is as sensitive and specific as a competing molecular test based on real

This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.

Quidel said this week that it has received the CE mark for its AmpliVue C. difficile assay, making it the first commercially available test using Quidel's non-instrumented format.

The company has developed a cartridge-based, multiplex, sample-to-answer molecular testing platform in the same vein as Cepheid, and hopes to begin clinical trials for its first two tests for detecting Staphylococcus aureus in blood culture and Clostridium difficile in stool by early summer.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.